Get started
Author

David Ali Rafei-Shamsabadi

Observed names: D Rafei-Shamsabadi, D. A. Rafei-Shamsabadi, D. Rafei-Shamsabadi, D. Rafei‐Shamsabadi, D.A. Rafei-Shamsabadi, David A Rafei-Shamsabadi, David A. Rafei-Shamsabadi, David Rafei, David Rafei-Shamsabadi, David Rafei‐Shamsabadi, Rafei, D., Rafei-Shamsabadi, David, Rafei-Shamsabadi, David A, Rafei-Shamsabadi, David Ali
Observed institutions: University of Copenhagen, Novartis (Switzerland), University of Freiburg, Philipps University of Marburg, University Medical Center Freiburg, Odense University Hospital, Bristol-Myers Squibb (United States), Dermatologie Freiburg
ORCID: 0000-0002-7850-3199
Observed ORCID: 0000-0002-7850-3199
OpenAlex ID: A5028357148
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
2017 · Markus V. Heppt, Lucie Heinzerling, et al. · European Journal of Cancer · 199
IgG Autoantibodies Against Desmocollin 3 in Pemphigus Sera Induce Loss of Keratinocyte Adhesion
2011 · David Rafei, Ralf Müller, et al. · American Journal Of Pathology · 97
PDF
MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors
2020 · Dominik Marschner, Martina Falk, et al. · JCI Insight · 89
PDF
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
2020 · Teresa Amaral, Felix Kiecker, et al. · Journal for ImmunoTherapy of Cancer · 88
PDF
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
2023 · Jürgen C Becker, Selma Ugurel, et al. · The Lancet · 83
Diagnostics in Hymenoptera venom allergy: current concepts and developments with special focus on molecular allergy diagnostics
2017 · Thilo Jakob, David Rafei-Shamsabadi, et al. · Allergo Journal International · 75
PDF
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients
2020 · Ulrike Leiter, Carmen Loquai, et al. · Journal for ImmunoTherapy of Cancer · 58
PDF
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity
2025 · Lukas M. Braun, Sophie Giesler, et al. · Cancer Cell · 57
Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases
2019 · Ricarda Rauschenberg, Johannes Bruns, et al. · European Journal of Cancer · 56
Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma
2020 · Jan Braune, Laura Keller, et al. · JCO Precision Oncology · 46
PDF
Phosphoinositide acyl chain saturation drives CD8+ effector T cell signaling and function
2023 · Joy Edwards-Hicks, Petya Apostolova, et al. · Nature Immunology · 41
PDF
Lack of Type 2 Innate Lymphoid Cells Promotes a Type I-Driven Enhanced Immune Response in Contact Hypersensitivity
2018 · David A. Rafei-Shamsabadi, Saskia van de Poel, et al. · Journal of Investigative Dermatology · 40
PDF
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study
2018 · Julia K. Tietze, Andrea Forschner, et al. · Oncotarget · 36
Context Dependent Role of Type 2 Innate Lymphoid Cells in Allergic Skin Inflammation
2019 · David A. Rafei-Shamsabadi, Christoph S. N. Klose, et al. · Frontiers in Immunology · 34
PDF
Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone
2019 · David Rafei-Shamsabadi, Saskia Lehr, et al. · Cancer Immunology Immunotherapy · 34
Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells
2024 · Zhen Zhang, Marlene Langenbach, et al. · Nature Immunology · 29
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases
2021 · Anne Zaremba, Manuel Philip, et al. · European Journal of Cancer · 25
Recombinant allergens rarely allow identification of Hymenoptera venom–allergic patients with negative specific IgE to whole venom preparations
2014 · David Rafei-Shamsabadi, Sabine Müller, et al. · Journal of Allergy and Clinical Immunology · 25
PDF
Proteomic Profiling of Fibroblasts Isolated from Chronic Wounds Identifies Disease-Relevant Signaling Pathways
2020 · Bettina Berberich, Kerstin Thriene, et al. · Journal of Investigative Dermatology · 24
PDF
Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma
2019 · B. Shannan, J. Matschke, et al. · European Journal of Cancer · 24
Differential IgG Recognition of Desmoglein 3 by Paraneoplastic Pemphigus and Pemphigus Vulgaris Sera
2012 · Oliver Brandt, David Rafei, et al. · Journal of Investigative Dermatology · 24
IgE recognition of chimeric isoforms of the honeybee (Apis mellifera) venom allergen Api m 10 evaluated by protein array technology
2014 · Matthias Van Vaerenbergh, Lina De Smet, et al. · Molecular Immunology · 23
MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study
2022 · Martin Salzmann, Johannes Pawlowski, et al. · European Journal of Cancer · 22
IgG against the Membrane-Proximal Portion of the Desmoglein 3 Ectodomain Induces Loss of Keratinocyte Adhesion, a Hallmark in Pemphigus Vulgaris
2022 · Christoph Hudemann, Yvonne Exner, et al. · Journal of Investigative Dermatology · 15
Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid—A Retrospective, Monocentric Study
2022 · Franziska Schauer, David Rafei-Shamsabadi, et al. · Frontiers in Immunology · 15
PDF
Works count: 67
Citation count: 1,377
H-index: 22
I10-index: 30
Year
Topic
Type